Fauna Bio, a biotechnology company pioneering the use of extreme mammal biology and comparative genomics to discover novel therapeutic targets, today announced the designation of a target under its ...
Boundless Bio's first direct ecDNA-targeting asset, is entering clinical trials with promising preclinical efficacy. Check ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results